Fundraising FoxVersant Ventures — 2024 Investments
6 investments dated 2024 · listed companies and verified rows first · show all
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Board seatTom WoiwodeAlex Mayweg· per SEC Form D
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVenrockAlexandriaBlackRockFidelity Investments+2 more
858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)inJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)
BoardAli Behbahani(Director)in
Board seatClare OzawaMonal MehtaCarlo Rizzuto· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Versant Venture Capital
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in
Co-investorsBroadview VenturesNovo HoldingsSR One Capital Management
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
Co-investorsWestlake Village BioPartners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Pep2Tango TherapeuticsSixPeaks Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.